Can artificial intelligence accelerate preclinical drug discovery and precision medicine?

Researchers

Journal

Modalities

Models

Abstract

Precision medicine leverages molecular biomarkers for selecting optimal treatment strategies. Accordingly, stratifying patients into responder and non-responder has strongly accelerated drug discovery and drug approvals in the last two decades. Recently, the applications of artificial intelligence (AI) in healthcare have been promoting these processes, and continue to improve patient care through systematically analysing large-scale molecular data and electronic health records. In particular, preclinical pharmacogenomics data empowered AI to unfold its full potential.Areas covered: Here, we discuss the opportunities of AI in pharmacogenomics, drug discovery and precision medicine. In particular, we shed some light on the advancements in computational biomedicine from statistical, machine learning (ML) to complex deep learning (DL) models.Expert opinion: AI has already strongly impacted drug discovery, and will continue to revolutionise academic research and the pharmaceutical industry. Its algorithms aid the identification of novel treatment options through molecular signatures and thus pave the way for the next generation of precision medicine.